Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Baxter Bros Inc.

Baxter Bros Inc. raised its position in Edwards Lifesciences Co. (NYSE:EW) by 3.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 87,824 shares of the medical research company’s stock after buying an additional 2,556 shares during the quarter. Baxter Bros Inc.’s holdings in Edwards Lifesciences were worth $6,502,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of EW. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $30,000. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $30,000. Finally, Avior Wealth Management LLC lifted its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Citigroup lifted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Piper Sandler increased their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Finally, Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

EW stock opened at $71.43 on Tuesday. The company has a 50-day simple moving average of $71.43 and a 200 day simple moving average of $70.42. The company has a market capitalization of $41.99 billion, a P/E ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.